S ince the first description of the AMP-activated protein kinase (AMPK) more than 20 years ago, 1 numerous studies have established a pivotal role of this enzyme in the regulation of cellular energy balance. Decreased cellular energy supply (indicated by an increased ATP breakdown and accumulation of AMP) leads to an AMPK-mediated adaptation to allow cellular survival. In doing so, AMPK acts as a cellular "fuel gauge," such that during nutrient deprivation it will inhibit energy-consuming pathways while it promotes energy producing pathways, eg, fatty acid oxidation or glycolysis. This simple principle is not only operative at the cellular level, because AMPK also governs whole body energy metabolism by the regulation of food intake in the hypothalamus. 2 Because the delivery of nutrients and oxygen to the tissue requires an intact vasculature, it is not surprising that AMPK also affects vascular growth and function. Previous studies revealed that AMPK promotes the production of endotheliumderived NO, acts as a proangiogenic signal, inhibits vascular smooth muscle proliferation, and prevents endothelial cell death. All these processes preserve and protect vascular function, an important precondition to provide tissue and cells with nutrients through an intact vasculature to maintain cellular energy levels. Because NO plays a fundamental role in vascular homeostasis, 2a the interaction between AMPK and endothelial NO synthase (eNOS) has gathered particular interest. Besides gene expression, the activity of eNOS is largely determined by posttranslational modifications such as multisite phosphorylation, subcellular localization, and eNOS-protein interactions. The eNOS phosphorylation sites associated with enzyme activation include Ser1177 and Ser633, whereas the phosphorylation site at Thr495 inhibits eNOS catalytic activity. Sitespecific phosphorylation also occurs at Ser114 and Ser615, but the functional consequences remain unclear. Several upstream kinases which modulate eNOS activity have been identified, including Akt, protein kinase (PK)A, PKC, and Ca 2ϩ /calmodulin-dependent protein kinase (CaMK)II (Figure) . AMPK enhances eNOS activity by direct phosphorylation at Ser1177 3 and by promoting its association with heat shock protein 90. 4 Initially, Thr495 phosphorylation by AMPK was reported in isolated enzyme preparations but was absent in cultured endothelial cells. 3 Several physiological stimuli are known to initiate AMPKmediated eNOS activation such as vascular endothelial growth factor, high-density lipoprotein, adiponectin, shear stress, hydrogen peroxide, ghrelin, thrombin, and estrogen. This has important functional implications in the vasculature, because AMPK-dependent NO production is essential for angiogenesis, allows differentiation of endothelial progenitor cells, limits myocardial ischemia/reperfusion injury, and inhibits platelet aggregation. Moreover, it may contribute to the pleiotropic effects of statins, peroxisome proliferator-activated receptor (PPAR)␥ agonists and metformin. In addition to direct eNOS activation, AMPK may also increase NO bioavailability indirectly by antioxidative mechanisms that prevent superoxide triggered NO consumption, eg, by inhibition of NADPH oxidase activity. 5 In this issue of Circulation Research, Chen et al demonstrate, for the first time, that AMPK can directly phosphorylate eNOS at Ser633, leading to endothelial NO production. 6 It is known that several stimuli leading to Ser1177 phosphorylation (eg, vascular endothelial growth factor, shear stress, and cAMP) also cause phosphorylation at Ser633. However, in contrast to the Ser1177 phosphorylation site, Ser633-mediated eNOS activation is slower and Ca-independent, so that it may serve to maintain NO production after an initial NO burst induced by Ser1177 phosphorylation. AMPK-dependent Ser633 eNOS phosphorylation was also observed in response to hormonal (adiponectin), physical (shear stress), and pharmacological (atorvastatin) stimuli, suggesting that this pathway is operative during diverse physiological and pharmacological signaling events. Experiments with aortic rings from mice lacking the ␣2AMPK isoform showed reduced eNOS phosphorylation at Ser1177 and Ser633, implicating ␣2AMPK as the major eNOS-regulating isoform. In addition, site-directed eNOS mutations demonstrated that Ser633 eNOS phosphorylation alone is sufficient for NO production, whereas its dephosphorylation prevented AMPK-dependent eNOS activation. Despite these intriguing observations, it remains to be established whether these signaling events are operative in vivo and whether they play a role during physiological or pathological vascular regulation. The variety of stimuli known to activate AMPK would suggest that the enzyme is constitutively active in the vasculature. During vascular disease, increased formation of reactive oxygen species or reactive nitrogen species is a common feature. In this respect, AMPK activation by hydrogen peroxide and peroxynitrite occurs in endothelial
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Several AMPK-mediated signaling pathways governing glucose metabolism can improve glycemic control and have implicated AMPK as a putative molecular target in the treatment of diabetes mellitus. Because antidiabetic drugs such as PPAR␥ agonists (glitazones) and metformin have AMPK activating properties and can also improve endothelial function, it is attractive to speculate that the observed protective vascular effects are caused by AMPKmediated eNOS activation. Because vascular complications are the leading cause of death in diabetic patients, a therapy with AMPK-activating drugs would fulfill 2 im-
Mechanisms of AMPK-dependent enhancement of NO bioavailability, including an illustration of eNOS phosphorylation sites (black indicates inhibitory; white, activation-associated; gray, undetermined) and their modulation by upstream kinases. For simplification purposes, an eNOS monomer is shown, although proper NO production requires the eNOS dimer. Phosphorylation sites are numbered according to the human eNOS sequence. AMPK can directly phosphorylate Ser1177 and Ser633, which are both associated with eNOS activation, causing an initial (Ser1177) and sustained (Ser633) NO release. Moreover, AMPK induces binding of heat shock protein 90 (hsp90) to eNOS, thus facilitating eNOS phosphorylation and its activation. In addition to increasing eNOS catalytic activity, AMPK may enhance NO bioavailability by limiting superoxide-triggered NO consumption and consecutive peroxynitrite (ONOO) production, eg, by inhibiting the NADPH oxidase (NOX). Other kinases involved in eNOS phosphorylation include Akt (Ser615, Ser1177), PKA (Ser633, Ser615), PKC (Thr495, Ser114), and CaMKII (Ser1177). BH 4 indicates tetrahydrobiopterin; CBD, calmodulin binding domain; FAD, flavin adenine dinucleotide; FMN, flavin adenine mononucleotide; L-arg, L-arginine; NADPH, nicotinamide adenine dinucleotide phosphate; O 2 Ϫ , superoxide anion.
portant goals: it improves glycemic control and may preserve endothelial function at the same time. However, PPAR␥ agonists and metformin activate AMPK indirectly by inhibition of the mitochondrial respiratory chain, so that the full potential of pharmacological AMPK activation might be achieved only with the development of more specific AMPK activators without these undesired side effects. Future animal and human studies are warranted and will determine whether AMPK can be established as a novel molecular target in the treatment of vascular disease.
